This article first appeared on GuruFocus .
Forty-two ETFs were buying Johnson & Johnson ( JNJ ) versus 21 selling in Thursday's session, for net buying of $35.1 million by dollar value. The move extended a four-day buying streak. Net inflows reached $46.4 million on Oct. 28, $2.5 million on Oct. 27 and $14.7 million on Oct. 26, after net selling of $34.7 million on Oct. 23. ETF activity left 154 funds holding the stock.
See all ETF and guru trades in JNJ on its JNJ guru trades page .
Which ETFs bought JNJ on Thursday?
The largest buyers by dollar value were XLV ($42.1 million), CGBL ($11.7 million) and DIA ($4.1 million). In all, 42 ETFs added shares and 21 cut them.
| ETF |
Shares changed |
Value |
Weight in ETF |
|---|---|---|---|
| +153,134 |
$42.1M |
9.95% |
|
| +42,651 |
$11.7M |
0.75% |
|
| +14,835 |
$4.1M |
3.12% |
|
| +9,053 |
$2.5M |
1.74% |
|
| +4,293 |
$1.2M |
22.18% |
|
| +3,317 |
$0.9M |
0.98% |
|
| +3,096 |
$0.9M |
4.99% |
|
| +2,884 |
$0.8M |
2.80% |
Health Care Select Sector SPDR ( XLV ) led the buying with a $42.1 million increase in value, lifting its stake 0.88% to 17,631,031 shares at a 9.95% weight. Capital Group Core Balanced ETF ( CGBL ) added $11.7 million, a 25.01% stake increase, while SPDR Dow Jones Industrial Average ETF ( DIA ) added $4.1 million and iShares Russell 1000 Value ETF ( IWD ) $2.5 million. iShares U.S. Pharmaceuticals ETF ( IHE ) added $1.2 million and holds the stock at a 22.18% weight. Johnson & Johnson operates in the Healthcare sector, in the Drug Manufacturers - General industry, with a market cap of $657.7 billion.
Have ETFs been buying or selling JNJ lately?
Over the last 5 reported days, ETFs were net buyers on 4 and net sellers on 1, so the recent trend is mostly buying.
| Date |
Net value |
Buying |
Selling |
|---|---|---|---|
| Oct. 29 |
$35.1M |
42 |
21 |
| Oct. 28 |
$46.4M |
33 |
11 |
| Oct. 27 |
$2.5M |
34 |
16 |
| Oct. 26 |
$14.7M |
25 |
15 |
| Oct. 23 |
-$34.7M |
26 |
17 |
What does JNJ do?
Johnson & Johnson, incorporated in New Jersey in 1887, is a holding company focused on products related to human health and well-being, with operating companies conducting business in virtually all countries and approximately 138,200 employees. It is organized into two segments.
Johnson & Johnson reported trailing-12-month revenue of $99.35 billion, up 7.0% year over year, with a gross margin of 67.7% and a net margin of 16.2%. The stock trades at a P/E of 41.44, P/B of 8.07 and P/S of 6.72, against a market cap of $657.7 billion. Its GF Score is 79, and the GF Value of $194.56 compares with a price of $273.20. The dividend yield is 1.99%, and the stock has returned 34.14% year to date.
JNJ at a glance
| Measure |
Value |
|---|---|
| Price |
$273.20 |
| Market cap |
$657.70B |
| Revenue (trailing 12 months) |
$99.35B |
| Revenue growth (1 year) |
+7.0% |
| Gross margin |
67.7% |
| Net margin |
16.2% |
| P/E |
41.44 |
| P/B |
8.07 |
| P/S |
6.72 |
| 79/100 |
|
| GF Value |
$194.56 |
| Dividend yield |
1.99% |
| Year-to-date return |
+34.14% |
Investors following JNJ can review its GF Value , guru trades and insider activity on the JNJ summary page .
See which funds are buying and selling on GuruFocus ETF Trends , or find and compare funds with the ETF Screener .
What should investors watch next for JNJ?
Watch whether the four-day buying streak continues after the $35.1 million net inflow, and whether buying breadth holds above the 21 funds that sold.
Based on ETF holdings changes reported for Oct. 29, 2026.
